Valley Fever Vaccine-various aspects-
While there are no approved vaccines for humans to prevent Valley Fever (coccidioidomycosis), efforts are underway to create one, according to the National Institutes of Health (NIH). Moreover, there is no vaccine for Rift Valley Fever (RVF) in humans; however, an inactivated vaccine is administered to at-risk lab personnel, with ongoing research focused on improving options, as per the National Institutes of Health (NIH).
Valley Fever (Coccidioidomycosis):
No vaccine currently available:
There is no vaccine authorized for human use to prevent coccidioidomycosis (Valley Fever).
Research ongoing:
Scientists are diligently working on creating a vaccine utilizing a gene-deletion mutant of Coccidioides posadasii, the fungus responsible for Valley Fever, in accordance with the National Institutes of Health (NIH).
Potential benefits:
This vaccine has yielded encouraging findings in animal testing and is being tested in human clinical trials.
If Any Patient of ENT Requires Any Surgery, Opd Consultation Or Online Consultation In Clinic of ENT Specialist Doctor Dr. Sagar Rajkuwar ,He May Contact Him At The Following Address-
Prabha ENT Clinic, Plot no 345,Saigram Colony, Opposite Indoline Furniture Ambad Link Road ,Ambad ,1 km From Pathardi Phata Nashik ,422010 ,Maharashtra, India-Dr. Sagar Rajkuwar (MS-ENT), Cell No- 7387590194, 9892596635
Rift Valley Fever (RVF):
No licensed human vaccine:
At present, there is no Rift Valley Fever vaccine that is licensed for widespread use in humans, though inactivated vaccines have been applied in specific situations.
Inactivated vaccine for at-risk personnel:
An experimental inactivated vaccine, TSI-GSD-200, is accessible for at-risk laboratory workers at the U. S. Army Medical Research Institute of Infectious Diseases.
Ongoing research:
Studies are in progress to formulate a safer and more efficient RVF vaccine for broader application, which includes a live attenuated vaccine (RVF MP-12).
Introduction
Rift Valley fever (RVF), caused by a phlebovirus from the Bunyaviridae family, frequently infects sheep, cattle, goats, and other domesticated animals of significant economic importance across various regions of sub-Saharan Africa. RVF was first brought to Egypt in 1977, leading to a significant outbreak that affected both domestic animals and humans and even reached the Nile delta near Cairo. While the virus seemed to vanish after 1980, it resurfaced in Egypt between 1993 and 1997. Most recently, RVF has been prevalent in the horn of Africa due to heavy rainfall associated with El Nino southern oscillation climatic conditions.
It is believed that RVF might be preserved in nature via transovarial transmission in floodwater Aedes mosquitoes, possibly enhanced by horizontal transmission of the virus among mosquitoes from infected vertebrates, including wild ungulates or even rodents. Once an outbreak occurs, epizootics in domestic animals can be maintained by numerous arthropods, including other species of mosquitoes and sandflies. The ability of the RVF virus to spread through various species of mosquitoes renders it a significant threat, as it could potentially be introduced into new regions where arthropod populations are dense and susceptible livestock are available.
RVF was initially identified in Kenya in 1931 and has since been determined to be endemic in many locations across sub-Saharan Africa. Besides being introduced into Egypt, it presents a serious concern in Madagascar, possibly linked to the ongoing ecological transformations on the island. By utilizing satellite remote sensing imagery techniques, Linthicum et al. were able to identify and possibly forecast RVF viral activity using parameters akin to the green vegetation index. Given the frequency of human travel, the dissemination of RVF virus among African countries and from Africa to other regions worldwide is quite feasible.
From a clinical perspective, the incubation period for RVF is roughly 3–4 days, followed by an abrupt onset of malaise, fever, chills, and headache. Involvement of additional organs could lead to meningo-encephalitis, retinitis, hepatitis, and kidney impairment. Severe cases may exhibit hemorrhage and often result in death. Relatively little information is available regarding the pathogenesis of the human disease; however, it has been effectively modeled in monkeys and rats. It is believed that endothelial infection results in widespread vascular damage and disseminated intravascular coagulation, along with extensive parenchymal infection of the liver.
To safeguard animals and people from contracting the RVF virus, a formalin-inactivated RVF virus vaccine (P-MKC) derived from monkey kidney cells infected with the pantropic strain of the virus was created (Randall et al. Randall et al. ). The vaccine prepared (NDBR-103) was assessed in mice and hamsters regarding immune response and effectiveness, as well as for its immune response in humans. As applied technologies have advanced, a more contemporary inactivated product, TSI-GSD-200, was developed and, following successful preclinical evaluation, was tested in humans. The experience gained with this vaccine lays the groundwork for this report. Additionally, a mutagenized live attenuated vaccine (MP-12) was developed for human application and thoroughly evaluated in domestic livestock, potential mosquito vectors, and laboratory animals; this vaccine must be assessed against the safety and efficacy standards established by TSI-GSD-200.
For Update On Further Important Health Related Topics And Frequently Asked Questions On Health Topics By General Population Please Click On The Link Given Below To Join Our WhatsApp Group –
https://chat.whatsapp.com/Lv3NbcguOBS5ow6X9DpMMA
According to the Centers for Disease Control Guidelines, everyone entering a biocontainment suite where RVF virus is utilized should receive vaccination. Although Kark et al. and Meadors et al. assessed the safety and immunogenicity of the TSI-GSD-200 vaccine, the clinical trials in earlier studies were shorter, involved fewer recipients, and only administered one booster to a smaller group of vaccinees. We provide the findings of a prolonged prospective, longitudinal study of the immunological response and safety of TSI-GSD-200 conducted from early 1986 through late 1997.
The RVF vaccine utilized in this research is TSI-GSD-200, a product that is formalin-inactivated and lyophilized, derived from the supernatant of cell cultures that were infected with the RVF virus. A plaque-cloned variant of the seed virus was produced, and an enhanced cellular substrate (diploid fetal rhesus lung cells, DBS 103) was employed and compared to the earlier NDBR 103 product. The final product (lots 1–20) was produced at the Salk Institute, Government Service Division, Swiftwater, PA. The lyophilized
Demographics
The initial 598 participants comprised 432 males (72%) and 166 females (28%). The overwhelming majority of the participant group were Caucasian (82%) and
Is there a vaccine for Valley fever in humans?
Prevention. Researchers are persistently developing a vaccine to avert Valley fever with minimal adverse effects. Currently, no vaccines are obtainable. It is extremely challenging to refrain from inhaling the fungus Coccidioides in regions where it exists in the surroundings.
What is the treatment for Valley fever in humans?
Numerous individuals who fall ill with Valley fever experience mild symptoms. They frequently recover without treatment within several months. Healthcare professionals might recommend 3-6 months of oral antifungal treatment such as fluconazole. This is intended for those with more severe infections or individuals with risk factors for serious infections.
Is there a vaccine for Rift Valley Fever for humans?
Rift Valley Fever Vaccines
The demand for widespread vaccination against RVF is restricted because RVF does not spread from person to person. A vaccine that has been inactivated has been created for human application; however, it is neither licensed nor available for commercial sale.
FOR INFORMATION IN GREAT DETAIL ON Valley Fever Treatment PL CLICK ON THE LINK GIVEN BELOW-It Is Always Better To View Links From Laptop/Desktop Rather Than Mobile Phone As They May Not Be Seen From Mobile Phone. ,In Case Of Technical Difficulties You Need To Copy Paste This Link In Google Search. In Case If You Are Viewing This Blog From Mobile Phone You Need To Click On The Three Dots On The Right Upper Corner Of Your Mobile Screen And ENABLE DESKTOP VERSION.
FOR INFORMATION IN GREAT DETAIL ON Valley Fever Symptoms PL CLICK ON THE LINK GIVEN BELOW-It Is Always Better To View Links From Laptop/Desktop Rather Than Mobile Phone As They May Not Be Seen From Mobile Phone. ,In Case Of Technical Difficulties You Need To Copy Paste This Link In Google Search. In Case If You Are Viewing This Blog From Mobile Phone You Need To Click On The Three Dots On The Right Upper Corner Of Your Mobile Screen And ENABLE DESKTOP VERSION.
FOR INFORMATION IN GREAT DETAIL ON Valley Fever Causes PL CLICK ON THE LINK GIVEN BELOW-It Is Always Better To View Links From Laptop/Desktop Rather Than Mobile Phone As They May Not Be Seen From Mobile Phone. ,In Case Of Technical Difficulties You Need To Copy Paste This Link In Google Search. In Case If You Are Viewing This Blog From Mobile Phone You Need To Click On The Three Dots On The Right Upper Corner Of Your Mobile Screen And ENABLE DESKTOP VERSION.
If Any Patient of ENT Requires Any Surgery, Opd Consultation Or Online Consultation In Clinic of ENT Specialist Doctor Dr. Sagar Rajkuwar ,He May Contact Him At The Following Address-
Prabha ENT Clinic, Plot no 345,Saigram Colony, Opposite Indoline Furniture Ambad Link Road ,Ambad ,1 km From Pathardi Phata Nashik ,422010 ,Maharashtra, India-Dr. Sagar Rajkuwar (MS-ENT), Cell No- 7387590194, 9892596635
Issued In Public Interest By –
www.entspecialistinnashik.com
